Jubilant Life Sciences Q3 profit falls 23.97pc at Rs 203.38 crore
Drug firm Jubilant Life Sciences on Friday reported a 23.97 per cent fall in consolidated net profit at Rs 203.38 crore for the third quarter ended on December 31, 2019.
New Delhi: Shares of Jubilant Life Sciences on Friday dropped nearly 4 per cent after the company reported a 23.97 per cent fall in consolidated net profit for the third quarter ended on December 31, 2019.
The scrip declined 3.55 per cent to close at Rs 581.95 on the BSE. During the day, it plunged 5.14 per cent to Rs 572.35.
On the NSE, it fell 3.89 per cent to close at Rs 579.20.
Also Read: Jubilant Life Sciences Arm Expands Drug Discovery Services Biz In Greater Noida, Bengaluru
Drug firm Jubilant Life Sciences on Friday reported a 23.97 per cent fall in consolidated net profit at Rs 203.38 crore for the third quarter ended on December 31, 2019.
It had posted a net profit of Rs 267.52 crore in the October-December quarter a year ago, Jubilant Life Sciences said in a BSE filing.
Net sales during the quarter under review stood at Rs 2,279.89 crore, down 3.11 per cent, as against Rs 2,353.08 crore in the corresponding period a year ago.
Also Read: Penalty Levied By SEBI On Jubilant Life Sciences Reduced To Rs 5 Lakh
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in. Check out more about our bureau/team here
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd